(Q33398947)

26 July 2017

title

Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies (English)

1 reference

26 July 2017

main subject

phase I clinical trial

0 references

1 reference

G S Falchook

1

1 reference

26 July 2017

M Duvic

2

1 reference

26 July 2017

D S Hong

3

1 reference

26 July 2017

J Wheler

4

1 reference

26 July 2017

A Naing

5

1 reference

26 July 2017

J Lim

6

1 reference

26 July 2017

R Kurzrock

7

1 reference

26 July 2017

publication date

29 December 2011

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

published in

1 reference

26 July 2017

volume

69

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

1117-1126

1 reference

Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Clinical and therapeutic aspects of extrapulmonary small cell carcinoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Synthesis of gemcitabine triphosphate (dFdCTP) as a tris(triethylammonium) salt

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Incorporating bortezomib into the treatment of lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Clinical update: proteasome inhibitors in solid tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Preclinical characteristics of gemcitabine.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Effect of Age and Sex on Human Drug Metabolism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Cancer in the elderly: basic science and clinical aspects

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4091047

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1808-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1808-4

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1808-4

Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1808-4

Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1808-4

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1808-4

Action of 2',2'-difluorodeoxycytidine on DNA synthesis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22205203

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22205203

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00280-011-1808-4

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference